June 2026 Research Update

Across these studies, a consistent message was that how dermatomyositis and related muscle diseases are tested matters: different commercial antibody tests, biopsy preparation methods, and monitoring tools can give different results. Several papers focused on reducing false positive or confusing results, especially when more than one antibody appears positive. Others described ways to expand access to useful testing in clinics that cannot do specialized procedures, or to monitor disease activity with less invasive techniques. [1] [2] [3] [4] [5] [6]

In a large multicentre Asia-Pacific study of 485 people with idiopathic inflammatory myopathies, two commercial blood tests for myositis-specific antibodies mostly agreed, but some antibodies showed meaningful mismatches. For anti-PL-7 and anti-Mi-2, follow-up testing more often suggested the line blot assay had false positive results, meaning it reported an antibody when it may not truly be present. The authors concluded the ELISA test appeared more accurate overall for these particular antibodies. [1]

A separate retrospective study of 235 people evaluated a modified way to set positive cutoffs for a line immunoassay (EUROLINE) with the goal of reducing reports of multiple antibodies being positive at the same time. Using the new positive control band index (PCBI) approach, 14 of 25 people with multiple-positivity by the standard cutoffs could be reclassified so fewer antibodies were considered positive, while 11 still had multiple positives. The authors suggested that adjusting cutoffs based on the clinical picture (phenotype-specific cutoffs) might improve test specificity, but this approach would need broader validation. [2]

For muscle biopsy testing, a small validation study (20 biopsy cases with a range of muscle diseases, including dermatomyositis) compared staining results from standard snap-frozen sections versus more widely available formalin-fixed, paraffin-embedded (FFPE) tissue. Three markers (MHC-II, MxA, and p62) could be reliably labeled in FFPE tissue with high agreement to frozen sections, while two others (MHC-I and MAC) did not work well in FFPE. This suggests some useful biopsy information may still be obtainable when frozen-section processing is not available, although marker choice matters. [3]

For monitoring, a two-center retrospective study in about 50 children with juvenile dermatomyositis found that nailfold capillaroscopy (microscope exam of small blood vessels near the fingernails) differed between active and inactive disease. Active disease more often showed lower capillary density, giant capillaries, and swelling around vessels, and these features correlated with a clinical disease activity score. The authors noted that prospective studies are needed to confirm how well this tool works for tracking changes over time. [6]

An exploratory device study described an ultrasoft skin-compatible electrode system to record surface electromyography (muscle electrical signals) in dermatomyositis. The researchers reported low-noise recordings and that the surface signals could be processed into measures of neuromotor function that showed strong agreement with gold-standard assessments, and they could detect differences between patients such as early muscle recruitment patterns. This work supports the idea that noninvasive muscle signal testing might contribute to monitoring, but the summary did not provide patient numbers or long-term outcome data. [4]

One case report highlighted that even biopsy can sometimes miss the diagnosis if the sampled muscle is not actively affected. In a 49-year-old man with severe dermatomyositis, an initial biopsy was non-diagnostic, but a whole-body nuclear medicine scan showed widespread uptake outside bone, and a gamma-probe-guided biopsy targeting metabolically active muscle supported the diagnosis along with anti-Mi-2 positivity. Because this was one patient, it mainly illustrates a possible approach for difficult-to-diagnose cases rather than a standard pathway. [5]

For patients and caregivers, this group of studies mainly adds background about why dermatomyositis test results can sometimes look inconsistent across labs or methods, especially for certain antibody tests and when multiple antibodies appear positive. It also shows that some monitoring approaches (like nailfold microscopy in children, or noninvasive surface muscle signal recording) are being studied as ways to track disease activity or muscle function without relying only on symptoms or invasive tests. What remains uncertain is how broadly these newer approaches apply across different clinics and patient groups, and how well they perform when used repeatedly over time in real-world care. [1] [2] [3] [4] [5] [6]

This month, studies looked at several types of care for dermatomyositis, ranging from a placebo-controlled drug trial to real-world treatment reviews and single-patient case reports. Overall, the research suggested that some therapies may lead to earlier improvement in specific problems like skin activity and itching, muscle-related symptoms, severe lung involvement, or swallowing difficulties, but most results were exploratory and not definitive. [7] [8] [9] [10] [11] [12]

In a prespecified secondary analysis of a phase 2 randomized, double-blind, placebo-controlled trial, dazukibart (an antibody that targets interferon beta signaling) showed early improvements in skin disease activity in the skin-predominant group and early signals of muscle-related improvement in the muscle-predominant group, with benefits maintained through Week 12. The skin-predominant group also showed early improvement in itching and skin-related quality of life measures compared with placebo. [7]

In a chart-review study of Acthar Gel across several autoimmune diseases, physicians reported improved health status after treatment in most adults recorded as having dermatomyositis/polymyositis, with commonly cited goals including better overall symptoms, strength or physical function, and reduced corticosteroid use. Because this was not a controlled study and relied on clinician-reported chart data, it cannot show how much improvement was due to the treatment versus other factors. [8]

Several case reports described intensive or add-on treatment approaches in individual patients, which can illustrate possibilities but may not apply to most people. One 10-year-old with MDA5-positive dermatomyositis and life-threatening lung failure on ECMO survived after compassionate-use CD19 CAR-T therapy, followed by immune system recovery and hospital discharge. [9]

Another case report described an adult with glucocorticoid-dependent dermatomyositis where adding ozone major blood ozonation over about 15 months coincided with lower muscle enzyme levels, healing of shoulder skin ulcers, less facial swelling, and fewer steroid-related side effects, with no adverse events reported in that patient. A separate case described a woman with systemic lupus erythematosus who developed dermatomyositis overlap syndrome and improved rapidly over days after a combination of treatments including corticosteroids, intravenous immunoglobulin (IVIg), methotrexate, and tailored physiotherapy. [10] [11]

In a 64-year-old with overlap inflammatory myopathy (PM/Scl-positive) and interstitial lung disease who did not have a rash, swallowing worsened even after muscle enzymes improved on corticosteroids, and improvement in swallowing and function was reported after IVIg was given. This single-patient report highlighted swallowing problems as a severe, day-to-day limiting symptom that may drive the need for treatments that can be given without swallowing pills. [12]

For patients and caregivers, this set of studies mainly adds context about what kinds of treatments are being tested and what symptoms researchers are measuring (skin rash activity and itching, muscle function, breathing and lung complications, and swallowing). Only one study here was a placebo-controlled clinical trial, so much of the other information comes from real-world chart review or single-patient experiences, which can describe what happened but cannot prove that a treatment will work similarly for others. Important uncertainties remain about who is most likely to benefit, how durable improvements are, and how to balance benefits with side effects, especially for complex cases involving the lungs or swallowing. [7] [8] [9] [10] [11] [12]

Several papers focused less on whether a drug works and more on how dermatomyositis and related myositis conditions are managed in real life, including access barriers, side effects seen in practice, and ways to monitor certain medicines. Overall, the studies suggested that treatment delivery and monitoring can vary widely across settings, and that some proposed monitoring or supportive programs remain early-stage. [13] [14] [15] [16] [17]

An international survey of 68 centers across 27 countries reported that intravenous immunoglobulin (IVIg) is commonly used for dermatomyositis and is often reserved for second- or third-line treatment, especially for swallowing problems, rapidly worsening disease, or refractory disease. Centers frequently reported infusion-related side effects such as headache and infusion reactions, and many reported cost and access barriers that differed by national wealth and development. [13]

In 23 people with dermatomyositis-associated interstitial lung disease treated with tacrolimus, an adjusted blood-exposure measure (based on hematocrit and lymphocytes) was linked to different clinical patterns: a low adjusted exposure ratio was tied to more lung disease flare-ups, while a high ratio showed a higher (not statistically significant) rate of acute kidney injury. This small observational study suggests that how tacrolimus exposure is measured might matter, but it does not establish the best monitoring approach. [14]

In children with juvenile dermatomyositis, a retrospective modeling study found tacrolimus handling in the body varied with body weight and with co-use of voriconazole, a medicine known to interact with tacrolimus. This was pharmacokinetic (drug-level) research rather than an outcomes study, so it informs how clinicians might think about variability in blood levels rather than proving clinical benefit. [15]

A small feasibility study tested a six-session narrative medicine program for children and young people with juvenile dermatomyositis or juvenile idiopathic arthritis and found high participation but no clear overall change in anxiety or depression scores, with a trend toward anxiety improvement in those who started with higher anxiety. Separately, a lab study using blood immune cells from seven dermatomyositis patients reported that stimulating the CB2 cannabinoid receptor reduced certain inflammatory signals more in amyopathic dermatomyositis cells than in classic dermatomyositis cells under specific lab conditions, which is background research rather than a tested treatment in people. [16] [17]

These studies are most relevant to understanding why care experiences can differ between clinics and countries (for example, IVIg access and cost), and why monitoring plans may vary for medicines like tacrolimus. For patients, the key takeaway is that some parts of dermatomyositis care are shaped by practical constraints and evolving monitoring methods, not just by the medication choice itself. What remains uncertain is whether newer monitoring measures, supportive programs, or lab-discovered targets will translate into better long-term health outcomes in larger, real-world patient groups. [13] [14] [15] [16] [17]

Across these papers, lung involvement was common in idiopathic inflammatory myopathies (immune diseases that can affect muscles and skin), and the most severe lung complications tended to track with worse short-term outcomes. Studies also pointed to recognizable clinical features and blood test patterns that were more frequent in rapidly progressive lung disease, but authors emphasized that more prospective research is needed to confirm which factors are truly predictive. [18] [19] [20] [21]

In a meta-analysis of 2,579 people with anti-MDA5 antibody-positive dermatomyositis, rapidly progressive interstitial lung disease was more likely in older patients, men, and in those who had fever, skin ulcers, or arthritis. People with rapidly progressive lung disease also tended to have higher inflammation-related blood markers (such as C-reactive protein, ferritin, and lactate dehydrogenase) and lower levels of some measures like lymphocyte counts and albumin, suggesting a pattern of stronger inflammation and lower immune cell counts in higher-risk cases. [18]

A retrospective study of 150 anti-MDA5 antibody-positive dermatomyositis patients focused on spontaneous pneumomediastinum (air leaking into the middle of the chest) and found higher 6-month mortality in those with this complication (54%) than those without it (16%). Within the pneumomediastinum group, people who died had higher inflammatory markers and shorter disease duration before the event, and infections were reported more often in the pneumomediastinum group, which may add to risk and complexity. [19]

In a prospective cohort of 86 Indian adults with idiopathic inflammatory myopathy, interstitial lung disease was present in 59.3% and showed several scan patterns, most often a nonspecific interstitial pneumonia (NSIP) pattern. Over about 1 year, 18.9% of evaluated interstitial lung disease patients progressed to progressive pulmonary fibrosis, and progression was linked to an amyopathic presentation and NSIP/organizing pneumonia patterns, suggesting that some scan and disease-subtype features may relate to worsening lung scarring over time. [20]

A small four-patient case series of acute exacerbation of interstitial lung disease (a sudden, severe worsening) reported that all four patients died, including one person with anti-MDA5-positive clinically amyopathic dermatomyositis. The accompanying narrative review highlighted that these sudden flare-ups often show rapid new changes on chest imaging, may be triggered by factors like infection or aspiration, and still lack standardized diagnostic criteria or proven treatments, making outcomes difficult to predict and compare across studies. [21]

One paper provided a protocol (plan) for a systematic review to standardize how interstitial lung disease related to idiopathic inflammatory myopathies is defined in both adults and children. While it does not address outcomes directly, it matters for outcome research because inconsistent definitions can make it harder to compare studies and to understand which lung patterns carry the highest risks. [22]

For patients and caregivers, these studies reinforce that when dermatomyositis (especially anti-MDA5 antibody-positive disease) involves the lungs, certain complications can be linked to serious short-term risk, and clinicians often look at symptoms (like fever) plus blood markers of inflammation and immune cell counts to understand severity. However, many results come from observational studies, and some reports are very small, so it remains uncertain which individual markers best predict what will happen for a specific person. Work to standardize definitions of myositis-related lung disease is mostly background research now, but it could make future studies on risk and outcomes easier to interpret and compare.

This months papers reinforced that dermatomyositis and related inflammatory muscle diseases can involve multiple organs beyond skin and muscle, including the gastrointestinal tract, metabolism (diabetes), the heart (as measured by heart scans and nervous system signals), and the lungs in uncommon overlap situations. The evidence here is mostly from observational cohorts, so it shows patterns and possible links rather than proving cause and effect. [23] [24] [25] [26]

In a retrospective dermatomyositis cohort, severe gastrointestinal involvement was reported more often in people with anti-NXP2 dermatomyositis than in other dermatomyositis subgroups, and included serious events like digestive tract perforations and bleeding. In the anti-NXP2 group, severe gastrointestinal involvement was seen more often in younger people and in those who had facial swelling at diagnosis, and it often happened when skin and/or muscle disease was also active. No deaths were reported in this study. [23]

A separate large retrospective study in adults found diabetes was more common in adult-onset dermatomyositis than in matched people without dermatomyositis. Importantly, more than half of diabetes diagnoses happened before glucocorticoid (steroid) treatment started, suggesting the higher diabetes rate was not only explained by steroid exposure in this dataset. Higher body mass index, high blood pressure, and abnormal cholesterol levels were linked with diabetes within the dermatomyositis group, while antibody status was not. [24]

In a small prospective study of idiopathic inflammatory myopathies (a group that includes dermatomyositis), measures of autonomic function (how the bodys automatic nervous system controls heart rate and blood pressure) were lower than in healthy controls and were linked with changes on a heart MRI marker (native T1). The study also reported test cutoffs that could signal heart involvement, but these cutoffs would need validation in other groups before being relied on broadly. [25]

A retrospective study of autoimmune pulmonary alveolar proteinosis (a rare lung condition) described a small subgroup who also had autoimmune diseases, including one person with dermatomyositis. In this series, most autoimmune diseases started before the lung condition, and some patients later developed lung scarring or died, while a few had chest CT improvement after stopping prednisolone; because dermatomyositis appeared in only one patient, this mainly serves as background about rare overlap rather than a dermatomyositis-specific risk estimate. [26]

For patients and caregivers, these studies add context for why clinicians may pay attention to symptoms and test results that involve organs other than skin and muscle in dermatomyositis. Right now, the clearest dermatomyositis-specific signal in this set is that severe gastrointestinal complications were reported more often in anti-NXP2 dermatomyositis, and that diabetes was more common in adult-onset dermatomyositis even when many cases started before steroid use. The heart and lung papers suggest additional ways other organs may be involved, but they are either small, not limited to dermatomyositis, or include very few dermatomyositis patients, so how often these apply to dermatomyositis overall remains uncertain. [23] [24] [25] [26]

Across this months studies, researchers used different kinds of patient features to sort dermatomyositis into subgroups, including symptoms (muscle weakness, swallowing problems), organ involvement (lungs, heart), and detailed descriptions of skin changes. Overall, the direction of results suggests that looking beyond a single label (like just having a rash or not) can capture meaningful differences, but most evidence here is exploratory and not yet confirmed in multiple settings. [27] [28] [29] [30] [31]

In a multicenter Turkish study of 176 children with juvenile dermatomyositis, researchers used computer-based clustering of 23 clinical and lab features to identify five groups with different typical patterns. These included a group with severe muscle weakness plus esophagus involvement (swallowing tube involvement), an amyopathic or low-muscle-involvement group, a skin-plus-lung-involvement group, a group with complicated skin disease, and a classic juvenile dermatomyositis group. Treatment patterns differed across groups, while tested blood antibody patterns were not clearly different between groups in this dataset. [27]

In 339 adults with anti-MDA5 positive dermatomyositis, one study proposed a detailed skin-phenotyping approach that tracked where ulcers occurred and whether there was itch or scale across several body regions. Any skin ulceration, and having ulcers in more sites, was linked with a signal of lower CD8 T cells in the blood, and facial ulceration was linked with pulmonary arterial hypertension in their analysis. The authors described these links as exploratory and in need of prospective confirmation. [28]

A smaller cross-sectional immune-profiling study (40 adults with idiopathic inflammatory myopathies) did not find a clear overall difference in basic blood lymphocyte subsets compared with healthy controls, but it did find that certain clinical features lined up with specific immune-cell patterns. Heart involvement was linked to higher double-positive CD4+CD8+ T cells, while swallowing problems and skin ulcers were linked to lower levels of the same cell type. Some antibody types (anti-Mi2 and anti-Ro52) were linked to shifts in natural killer cells and B cells. [29]

Two skin-focused studies added biological detail that could eventually support more refined subgroups based on what is happening in the skin itself. A biopsy study comparing 22 dermatomyositis samples with controls found more deposition of complement (C3c) and certain antibody types (IgM and IgA) at the damaged skin layer, and found MDA5 protein more visible in dermal inflammatory cells and small blood vessels in dermatomyositis skin. [30] An additional study using spatial and single-cell RNA methods reported different immune and blood-vessel related tissue patterns in cancer-associated versus non-cancer-associated adult dermatomyositis lesions, including prominent myeloid inflammatory signals near injured blood-vessel lining in non-cancer cases. [31]

For patients and caregivers, these studies help explain why two people with dermatomyositis can have very different combinations of muscle weakness, swallowing trouble, lung disease, and skin problems, and why researchers are trying to name and measure those patterns more precisely. Right now, the work is mainly background research: most results are retrospective or cross-sectional and described as exploratory, meaning they can suggest useful subgroups but cannot yet reliably predict what will happen for an individual person. What remains uncertain is which grouping approach (symptom clusters, detailed skin mapping, blood immune-cell patterns, or skin tissue signatures) will hold up across different hospitals and over time, and which ones will meaningfully relate to long-term outcomes. [27] [28] [29] [30] [31]

Across these papers, the main pattern was that dermatomyositis can sometimes be a paraneoplastic condition, meaning it appears in the setting of an underlying cancer. The reports describe several different cancer types rather than one single cancer that always appears, and they show mixed outcomes ranging from remission to death, which highlights uncertainty at the individual level. [32] [33] [34] [35] [36]

In one report, a 58-year-old man had dermatomyositis with kidney problems caused by muscle breakdown products (myoglobin nephropathy), and the work-up identified smouldering multiple myeloma (a plasma cell cancer). The authors used this case to argue that checking for plasma cell disorders can sometimes uncover an underlying cancer in dermatomyositis. [32]

Two reports described situations where a hidden cancer was found only after further testing. A woman in her twenties had steroid-refractory dermatomyositis and was found to have an occult breast cancer detected on breast MRI after an axillary lymph node biopsy, and her dermatomyositis went into complete remission after cancer treatment. [35]

A 51-year-old woman with new dermatomyositis was later diagnosed with gastroesophageal junction adenocarcinoma after progressive trouble swallowing, and she died from pneumonia related to Pseudomonas sepsis during cancer treatment. This case highlights that serious infections can occur during complex cancer and immune-suppressing care, but it does not prove this will happen to others. [34]

Another case involved a 35-year-old woman with anti-TIF1-gamma positive dermatomyositis and an adenocarcinoma where the primary site was not found, and both the cancer and dermatomyositis reached complete remission after a multi-part treatment plan (including chemotherapy, pembrolizumab, surgery, and radiotherapy). The report also noted that her dermatomyositis did not worsen while she received pembrolizumab, though this is evidence from a single patient. [33]

A separate report described a 49-year-old man with TIF1-gamma positive dermatomyositis who developed unusual rash patterns (the deck chair sign and reverse waistband sign), had initial improvement on steroids and intravenous immunoglobulin, then relapsed and died from gastrointestinal perforation during hospitalization. The authors mentioned a paraneoplastic work-up, but this paper primarily adds detail about skin patterns and severe complications in one person rather than establishing a consistent cancer link. [36]

For patients and caregivers, these papers mainly add background about the range of cancers that have been reported alongside dermatomyositis and how cancer discovery can sometimes explain difficult-to-control symptoms. Because the evidence here is mostly single-patient case reports, it cannot estimate how often any cancer occurs in dermatomyositis or predict an individual persons risk. It also remains uncertain which tests or screening approaches best fit different people, since these papers describe very different situations and outcomes.

These papers suggest two ways infections may relate to dermatomyositis: as a difficult-to-recognize infection happening around the time of diagnosis, and as a broader connection between HIV and autoimmune conditions that can include dermatomyositis. Overall, the evidence is mixed and often indirect, comprising case reports and cross-sectional (snapshot-in-time) studies that cannot prove cause and effect. [37] [38] [39] [40]

In one patient with newly diagnosed dermatomyositis, subacute Bartonella quintana bacteremia (a bloodstream infection) was hard to confirm because routine testing was inconclusive, and nanopore sequencing was used to identify the germ. The patient improved rapidly after treatment with doxycycline and anti-inflammatory therapy, showing how an infection can complicate the picture and how advanced testing may help in select situations. [37]

In a symptom-directed screening study of 129 people living with HIV, antinuclear antibodies were common and one person was identified as having dermatomyositis. This study focused more on lupus testing than on dermatomyositis specifically, but it supports that autoimmune diseases, including dermatomyositis, can occur in people with HIV. [38]

A nationwide Korean cross-sectional analysis comparing people living with HIV on antiretroviral therapy with the general population found no clear difference in overall autoimmune disease prevalence. However, dermatomyositis in women was reported as more common in the HIV group, and the authors emphasized that this was based on very small case numbers and should be considered hypothesis-generating rather than definitive. [39]

In a pediatric case report, an 8-year-old girl had overlapping autoimmune conditions (neuromyelitis optica spectrum disorder, clinically amyopathic dermatomyositis, and secondary hemophagocytic lymphohistiocytosis), and Epstein-Barr virus (EBV) DNA was detected as a possible trigger. She recovered fully after aggressive immune-directed therapy, but this is a complex overlap case and does not establish that EBV causes dermatomyositis in general. [40]

For patients, this group of studies mainly provides context that infections and immune changes related to HIV have been reported alongside dermatomyositis, but the strength of evidence varies. The Bartonella and pediatric overlap papers are single-patient reports, so they illustrate possibilities rather than typical experiences. The HIV studies are snapshots in time and include small numbers of dermatomyositis cases, so it remains uncertain whether HIV truly increases dermatomyositis risk, which groups might be most affected, and what biological mechanisms are most important.

Across this month's research in this topic area, the main message was that recovery of pain, function, and quality of life after hip replacement can look similar in people with dermatomyositis compared with people without dermatomyositis, but breathing-related complications may be more common after surgery. Evidence is limited because the study was small and retrospective, so it cannot fully explain which patients are most at risk. [41]

In a retrospective, 1:2 matched case-control study of primary total hip arthroplasty (hip replacement), both dermatomyositis and non-dermatomyositis groups had comparable improvements in patient-reported pain, hip function, and overall quality of life at about 5 years of follow-up. [41]

Breathing complications after surgery were reported more often in the dermatomyositis group (4 of 21 operations) than in matched controls (0 of 42 operations). Within the dermatomyositis group, higher preoperative D-dimer blood levels were linked to these breathing events, but this was described as a preliminary signal in a small sample. [41]

For patients and caregivers, this study mainly provides near-term, practical context for what recovery might look like after hip replacement in dermatomyositis: improvements in pain and function were similar to people without dermatomyositis in this small dataset, while breathing problems shortly after surgery were more common. It is still uncertain how well these results apply to other surgeries, larger groups of patients, or people with different lung involvement, because the study was small and done at a single center. [41]